drugset / Trial / NCT01708590
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-05
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |